logo
  

Lear Corp. Q4 Earnings Plunge, But Beat Estimates

Lear Corporation (LEA) on Tuesday reported net income of $21.5 million or $0.36 per share in the fourth quarter, significantly lower than $201.6 million or $3.33 per share in the same quarter a year ago. The results reflected decline in vehicle production due to the worldwide semiconductor shortage . However, earnings surpassed the Street estimates.

Excluding one-time items, earnings were $73.6 million or $1.22 per share. This compares with the average estimate of analysts polled by Thomson Reuters at $1.1 per share. Analysts' estimates typically exclude special items.

Sales for the quarter declined 7% to $4.879 billion from $5.243 billion last year, impacted by decrease in global vehicle production due to semiconductor shortage. The consensus estimate was for $4.72 billion.

Looking forward to 2022, the company expects net sales to be in the range of $20.8 billion-$22.3 billion. Analysts' expectation for sales stands at $23.33 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT